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A b s t r a c t
This review discusses the response variability to acetylsalicylic acid (ASA) and particularly to clopidogrel, and their relation 
to adverse recurrent ischaemic events in patients with arterial diseases. The higher rate of ASA resistance reported in the 
literature may be mainly due to the cyclooxygenase-1 non-specific assays, non-compliance, and underdosing. Clopidogrel 
response variability and non-responsiveness are established concepts. Moreover, high platelet reactivity (HPR) to adenosine 
diphosphate during clopidogrel therapy is now a known risk factor for recurrent ischaemic events in high-risk percutaneous 
coronary intervention/acute coronary syndrome patients. Variable active metabolite generation is the primary explanation for 
clopidogrel response variability and non-responsivenes. Variable levels of active metabolite generation following clopidogrel 
administration could be mainly explained by functional variability in hepatic cytochrome (CYP)P450 isoenzyme activity that 
is influenced by drug–drug interactions and single nucleotide polymorphisms of specific genes encoding CYP450 isoen-
zymes. Treatment with more potent P2Y12 receptor blockers, such as prasugrel and ticagrelor are credible alternative strategies 
to overcome HPR during clopidogrel therapy.
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INTRODUCTION
Multiple lines of evidence from translational research support 
the pivotal role of platelet function in arterial thrombotic 
event occurrences, particularly in patients with acute coro-
nary syndromes (ACSs) [1]. In ex vivo experimental models 
of arterial thrombogenesis using human blood samples, 
combined therapy of a P2Y12 receptor blocker, clopidogrel, 
with acetylsalicylic acid (ASA) dramatically potentiated the 
antithrombotic effect of each drug alone [2]. Large scale land-
mark clinical trials have demonstrated the superior efficacy of 
clopidogrel and ASA therapy vs. ASA therapy alone in patients 
with coronary artery diseases (CADs). Based on this evidence, 
dual antiplatelet therapy of ASA and a P2Y12 receptor an-
tagonist is the cornerstone of secondary prevention therapy 
for patients presenting with ACS and in those treated with 
percutaneous coronary intervention (PCI) with stenting [3]. 
Multiple observational pharmacodynamic studies have dem-
onstrated the response variability to ASA and particularly 
to clopidogrel, and their relation to adverse recurrent ischae-
mic event occurrence in patients with arterial diseases. The 
pharmacological limitations and treatment failure associated 
with clopidogrel therapy fostered the development and 
clinical implementation of the more effective P2Y12 receptor 
blockers, prasugrel and ticagrelor [4, 5]. Landmark clinical 
trials involving patients with ACS unequivocally demonstrated 
the greater anti-ischaemic effects of these agents compared 
to clopidogrel, supporting the “platelet hypothesis” concept 
that greater platelet inhibition results in greater reduction in 
ischaemic outcomes [6, 7]. In this review article, we discuss 
the recent developments in hyporesponsiveness/resistance to 
ASA and clopidogrel in patients with ACS. 
ACETYLSALICYLIC ACID
Acetylsalicylic acid irreversibly inhibits cyclooxygenase 
(COX)-1 activity, thereby inhibiting thromboxane A2 (TxA2)-
-induced platelet activation and aggregation, whereas P2Y12 re-
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ceptor blockers inhibit adenosine diphosphate (ADP)-induced 
platelet activation and aggregation [8]. In addition, ASA has 
been shown to exhibit numerous pleiotropic effects that might 
influence its antithrombotic efficacy [9]. Based on laboratory 
findings, earlier studies have reported that up to 50% of 
patients with atherosclerotic disease are “resistant” to ASA 
therapy (“laboratory ASA resistance”), and these patients may 
be at increased risk of recurrent ischaemic events. A reliable 
and specific laboratory method to identify ASA resistance has 
not yet been uniformly accepted by investigators. Because 
TxA2 is an important secondary agonist that is released fol-
lowing platelet activation in response to shear, ADP, collagen, 
and epinephrine, various assays utilising the latter agonists have 
been wrongly used to indicate antiplatelet response of ASA. 
Therefore, laboratory methods including point-of-care meth-
ods using the latter agonists do not solely indicate COX-1 activ-
ity (COX-1 non-specific methods) and thus are fundamentally 
flawed in indicating antiplatelet response to ASA. The optimal 
definition of resistance or non-responsiveness to ASA is the 
demonstration of residual activity of the COX-1 enzyme. Meas-
urement of serum thromboxane B2 (TxB2) and arachidonic 
acid-induced platelet aggregation are the most specific assays 
to indicate COX-1 ASA responsiveness (COX-1–specific meth-
ods). The ASA resistance is more meaningful only when it is 
associated with elevated risk for ischaemic event occurrences. 
Depending on the patient population, type of assay, 
cut-off points for “normal” value dose, and ASA dose, esti-
mates of the prevalence of ASA resistance have been reported 
between < 1% and 55% [8]. A true pharmacological ASA 
“resistance” is rare when measured by methods that solely 
indicate inhibition of COX-1 activity such as arachidonic acid 
(AA)-induced platelet aggregation [8–13]. The higher rate of 
ASA resistance reported in the literature may be mainly due 
to the COX-1 non-specific assays described above, non-com-
pliance, and underdosing — particularly in high-risk patients. 
In the recently reported ADPT-DES study of 8582 patients 
with CAD treated with ASA and clopidogrel after successful 
drug-eluting stent implantation, ASA hyporesponsiveness 
(> 250 ASA reaction units by VerifyNow Aspirin assay) was 
observed in only 5.6% of patients, and it was not associated 
with adverse outcomes [14].
Using urinary 11-dh-TxB2 metabolite levels to assess ASA 
responsiveness among patients at high risk for cardiovascular 
events enrolled in the Heart Outcomes Prevention Evaluation 
(HOPE) trial, Eikelboom et al. [15] found that patients in the 
upper quartile have a higher risk of myocardial infarction (MI), 
stroke, or cardiovascular death vs. lower quartile (odds ratio 
[OR] 1.8; 95% confidence interval [CI] 1.2–2.7; p = 0.009). 
Similarly, subanalysis of the Clopidogrel for High Athero-
thrombotic Risk and Ischaemic Stabilisation, Management, 
and Avoidance (CHARISMA) study indicated that the highest 
quartile of urinary 11-dh-TxB2 metabolite levels was associ-
ated with an increased risk of stroke, MI, or cardiovascular 
death compared to the lowest quartile (adjusted hazard ratio 
[HR] 1.66, 95% CI 1.06–2.61, p = 0.03) in patients treated 
with ASA. Moreover, treatment with ≥ 150 mg/dL ASA was 
associated with lower urinary 11-dh-TxB2 levels, indicating 
a dose-dependent effect. These are the only studies that 
demonstrated a strong link between ASA responsiveness 
and clinical outcomes. However, it should be noted that 
11-dh-TxB2 represents whole-body TxB2 production and may 
be influenced by non-platelet sources, especially in pathologi-
cal conditions of inflammation and high-risk cardiovascular 
disease [16]. Currently, there is no established method to 
assess ASA responsiveness, nor is there a definition of “ASA 
resistance,” and its relevance in patients with ACS in unknown. 
Moreover, the clinical effectiveness of altering therapy based 
on a laboratory finding of ASA “resistance” has not been 
explored. Therefore, other than in research trials, it is not 
currently recommended to test for ASA resistance in patients 
or to change therapy based on such tests. 
CLOPIDOGREL RESPONSE VARIABILITY,  
CLOPIDOGREL RESISTANCE, AND HIGH  
ON-TREATMENT PLATELET REACTIVITY
Clopidogrel is still the most widely used P2Y12 receptor blocker 
to treat patients with arterial diseases. Clopidogrel is a prodrug 
that requires hepatic conversion into an active metabolite to 
exert its antiplatelet response. Only ~15% of the absorbed 
clopidogrel is metabolised by hepatic cytochrome (CYP) 
P450 isoenzymes in a two-step process involving cytochrome 
(CYP) 2C19, CYP3A, CYP1A2, CYP2B6, and CYP2C9. The 
highly unstable active metabolite covalently binds to platelet 
P2Y12 receptor specifically and irreversibly resulting in inhibi-
tion of ADP-induced platelet activation-aggregation for the 
lifespan of the platelet [17, 18]. 
In 2003, clopidogrel response variability and resist-
ance was first demonstrated using conventional platelet ag-
gregometry and flow cytometry studies in patients undergoing 
PCI, who had received a 300-mg loading dose followed by 
75-mg daily maintenance dose of clopidogrel [19]. Since 
then, numerous studies using various assays to measure 
ADP-induced platelet reactivity and involving thousands of 
patients conducted around the world reported pharmaco-
logical “resistance” to clopidogrel and indicated clopidogrel 
non-responsiveness where a substantial percentage of patients 
(up to 35%) exhibited either negligible or no antiplatelet 
response to clopidogrel [4, 5]. Multiple lines of evidence 
strongly suggest that variable active metabolite generation is 
the primary explanation for clopidogrel response variability 
and non-responsiveness. Variable levels of active metabolite 
generation following clopidogrel administration could be 
mainly explained by functional variability in hepatic P450 iso-
enzyme activity that is influenced by drug–drug interactions 
and single nucleotide polymorphisms (SNPs) of specific genes 
encoding CYP450 isoenzymes [4]. 
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Single nucleotide polymorphisms of CYP2C19 genes 
(loss-of-function allele carriers) have been associated with 
variable pharmacokinetic and pharmacodynamic response 
as well as elevated ischaemic risk in clopidogrel-treated pa-
tients who have undergone PCI [20]. It should be noted that 
the CYP2C19 isoenzyme is not the only factor determining 
the antiplatelet response to clopidogrel, because even in 
poor metabolisers some degree of platelet inhibition has 
been observed where no enzyme activity is expected [21]. 
In addition, numerous demographic and epigenetic factors 
influence antiplatelet response independently of genetic 
polymorphisms of CYP2C19 gene (Figs. 1, 2) [5, 22]. There-
fore, SNPs of CYP2C19 may not be a surrogate indicator of 
clopidogrel resistance or platelet reactivity to ADP, and the 
assessment of platelet reactivity to ADP is more suitable to 
identify high-risk patients and to treat with personalised an-
tiplatelet therapy strategy.
HIGH PLATELET REACTIVITY TO ADP 
The level of on-treatment platelet reactivity may be a superior 
risk predictor compared to the assessment of clopidogrel 
resistance (difference between baseline and post-treatment 
platelet reactivity) because platelet reactivity to ADP has 
been shown to be variable before clopidogrel treatment 
in patients on ASA therapy [23]. It has been demonstrated 
that high platelet reactivity (HPR) to ADP during clopidogrel 
treatment is a strong and independent risk factor for post-PCI 
thrombotic events. Numerous observational studies confirmed 
the relation of HPR to post-PCI ischaemic events including 
periprocedural events, long-term events, and stent throm-
bosis (ST). A consensus opinion on the definition of HPR 
based on various methods of platelet function testing (PFT) 
has been reported [4, 5]. Based on accumulating data from 
the observational studies, American and European practice 
guidelines have issued a class IIb recommendation for PFT 
to facilitate the choice of P2Y12 receptor inhibitor in selected 
high-risk patients treated with PCI, although routine testing 
is not recommended (class III) [24–26].
In the Assessment of Dual Anti-Platelet Therapy with 
Drug-Eluting Stents (ADAPT-DES) study involving more 
than 8500 patients, nearly half of these patients had ACS 
(unstable angina 28%, non-ST-segment elevation MI 15%, 
and ST-segment elevation MI 9%). In this study, 43% of 
patients met the criteria of HPR (> 208 P2Y12 reaction units 
[PRU]), and PRU > 208 was independently associated with 
an approximately 4-, 1.5-, and 1.8-fold increase in the risk 
of definite/probable ST at 0 to 30 days (HR 3.90; 95% CI 
1.90–8.00; p < 0.001), 30 days to one year (HR 1.55; 95% 
CI 0.76–3.18; p = 0.23), and two years (HR 1.84; p = 0.009) 
in landmark analyses, respectively [27, 28]. The relation of 
HPR and ischaemic event occurrences was more pronounced 
in patients with ACS compared to patients with stable CAD 
(adjusted HR 2.60, p < 0.005 and 1.44, p = 0.47, respec-
tively). The ADAPT-DES study also demonstrated a strong 
Figure 1. Various factors influencing platelet reactivity and clinical events during clopidogrel therapy; ADP — adenosine dipho- 
sphate; BMI — body mass index; CAD — coronary artery disease; CCB — calcium channel blocker; CYP — cytochrome P450;  
DDI — drug–drug interaction; HPR — high on-treatment platelet reactivity; LPR — low on-treatment platelet reactivity; PPI —  
proton pump inhibitor; PRU — P2Y12 reaction units; SJW — St. John’s wort; SNP — single nucleotide polymorphism.  
Adapted from [22]
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inverse relationship between > 208 PRU and major bleeding 
(HR 0.65, p = 0.04) [28]. 
In an analysis of studies including 20,839 patients (97% 
were treated with clopidogrel and 3% with prasugrel), patients 
with HPR in contrast to optimal platelet reactivity had signifi-
cantly higher risk of ST (risk ratio [RR] 2.73, p < 0.001) and 
a slight reduction in bleeding (RR 0.84, p = 0.04) compared 
to those with optimal platelet reactivity, whereas patients 
with low platelet reactivity (LPR) had a higher risk of bleeding 
(RR 1.74, p < 0.001), without any further benefit in ST (RR 
1.06, p = 0.78) [29]. A systematic review and meta-analysis of 
individual patient data on major adverse cardiac event (MACE) 
outcomes (ACS, ischaemic strokes, and vascular deaths) in rela-
tion to platelet reactivity and their interaction with cardiovascular 
risk levels revealed that the magnitude of the association between 
platelet reactivity and MACE risk is strongly dependent on the 
level of cardiovascular risk faced by patients on clopidogrel [30].
In addition to the upper threshold for ischaemic risk (i.e. 
HPR), small translational research studies have demonstrated 
the relation of LPR with bleeding. The concept of a “therapeu-
tic window” of P2Y12 receptor reactivity associated with both 
ischaemic event occurrence (upper threshold) and bleeding 
risk (lower threshold) has been proposed. A consensus docu-
ment highlighting the above observations with a therapeutic 
window concept with updated cut-off for HPR and LPR 
for P2Y12 inhibitor therapy has been published (Fig. 2) 
[28, 31–34]. This approach is more meaningful while titrat-
ing the dose of more potent P2Y12 receptor blockers that 
are known to be associated with increased incidences of 
bleeding. These observations provided a strong rationale to 
measure platelet response to ADP during clopidogrel therapy 
and to personalise antiplatelet therapy based on the therapeu-
tic window concept to reduce both ischaemic and bleeding 
events in high-risk CAD patients undergoing PCI. Moreover, 
newer P2Y12 receptor blockers such as prasugrel and ticagrelor 
have been shown to have superior pharmacodynamic effects 
and improved clinical outcomes in ACS patients. Prasugrel and 
ticagrelor are associated with elevated risk for bleeding, and 
a uniform and long-term therapy with these agents may be as-
sociated with elevated bleeding risk. Therefore, they are good 
alternative agents to overcome the limitations of clopidogrel 
in selected patients who exhibit HPR phenotype and low risk 
of bleeding. The utility of platelet function measurement in 
personalising antiplatelet therapy has been addressed in recent 
large-scale randomised trials. 
RANDOMISED STUDIES OF PERSONALISED  
ANTIPLATELET THERAPY 
Despite strong evidence linking HPR to ischaemic events 
from numerous observational studies, prospective, ran-
domised trials have failed to demonstrate that personalised 
antiplatelet therapy based on platelet function is effective 
in reducing ischaemic event occurrences (Table 1) [35–39]. 
These studies have fundamental problems. The majority of 
them enrolled low-risk patients, and therefore the associated 
ischaemic event occurrence was low (i.e. underpowered), 
they mainly used high-dose clopidogrel, which is not optimal 
to reduce HPR, and therefore the risk reduction was not 
significant (undertreated), and all these studies used Veri-
fyNow P2Y12 assay to identify HPR phenotype. Furthermore, 
Figure 2. Therapeutic window concept for P2Y12 receptor blockade; ACS — acute coronary syndrome; BMI — body mass  
index; CABG — coronary artery bypass grafting; DM — diabetes mellitus; MEA-AU — multiplate analyser-arbitrary units;  
PRU — P2Y12 reaction units; ST — stent thrombosis; TEG-MA — thromboelastography–maximum ADP-induced platelet fibrin  
clot strength; VASP-PRI — vasodilator stimulated phosphoprotein phosphorylation-platelet reactivity index. Adapted from [5]
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in the ANTARCTIC study, the therapeutic approach in the 
PFT group was primarily to reduce bleeding. Therefore, the 
results of these studies should not be considered to disap-
prove the utility of PFT in improving clinical outcomes. At 
the same time, smaller studies have suggested that the 
PFT-directed approach may be effective with proper im-
plementation [5]. Finally, in the absence of evidence from 
a randomised study, selective and optional use of PFT to 
guide P2Y12 inhibitor therapy is reasonable to consider in 
selected high-risk patients, such as those in whom ACS risk 
of excessive bleeding is low. 
In addition, de-escalation of P2Y12 inhibitor therapy 
to reduce bleeding risk has been suggested. In the recently 
published Testing Responsiveness to Platelet Inhibition on 
Chronic Antiplatelet Treatment For Acute Coronary Syn-
dromes (TROPICAL-ACS) trial, ACS patients with successful 
PCI were randomised to a standard treatment with prasu-
grel for 12 months (control group) or one week prasugrel 
therapy followed by one week clopidogrel and PFT-guided 
maintenance therapy with clopidogrel or prasugrel from day 
14 after hospital discharge (guided de-escalation group). The 
combined primary endpoint of cardiovascular death, MI, 
stroke, or bleeding grade 2 or higher according to Bleeding 
Academic Research Consortium (BARC) criteria was similar 
(9% vs. 7%) (pnon-inferiority = 0.0004; HR 0.81, 95% CI 0.62–1.06, 
psuperiority = 0.12). There was no increase in the combined risk 
of cardiovascular death, MI, or stroke and a non-significant 
increase in the BARC 2 or higher bleeding in the de-escalation 
group vs. in the control group [39]. The study provided a strong 
rationale for the de-escalation of prasugrel therapy in ACS 
patients managed with PCI. 
CONCLUSIONS
Clopidogrel response variability and non-responsiveness are 
established concepts. Moreover, HPR during clopidogrel 
therapy is now a known risk factor for recurrent ischae-
mic events in high-risk PCI/ACS patients. However, the 
TRILOGY-ACS platelet function substudy and other studies 
suggest that the clinical relevance of HPR in patients with 
medically managed ACS or stable CAD is less clear [40, 41]. 
Treatment with high-dose clopidogrel (600 mg loading dose 
plus 150 mg maintenance dose) is not an optimal strategy 
to overcome HPR and to reduce frequency of recurrent 
ischaemic events. Whereas, treatment with more potent 
P2Y12 receptor blockers, such as prasugrel and ticagrelor, 
is associated with faster and greater platelet inhibition than 
clopidogrel therapy and is a credible alternative strategy to 
overcome HPR during clopidogrel therapy. However, recent 
data indicate that prasugrel and ticagrelor therapies are associ-
ated with a delayed pharmacodynamic effect after stenting in 
ACS patients. The two major randomised trials of personalised 
antiplatelet therapy failed to confirm the benefit of PFT to 
improve outcomes. However, these studies were underpow-
ered given the low risk of the enrolled patients, and they used 
high-dose clopidogrel as the remedy for HPR. Currently we 
do not have an adequate evidence base to support or refute 
the clinical utility of platelet function testing in the high-risk 
patient. What we do have are an unshakable biologic rationale 
and a robust body of data linking HPR to thrombotic events 
in the high-risk patient treated with PCI.
In ACS patients enrolled in the TRITON-TIMI trial, the 
greatest anti-ischaemic benefit of prasugrel was observed early 
after ACS and PCI, whereas long-term therapy was associated 
with elevated bleeding risk [6]. Similarly, in the PLATO trial, 
in patients treated with PCI, reduction in ST associated with 
ticagrelor therapy was most prevalent in the first 30 days after 
the procedure, and again increased bleeding risk was appar-
ent during long-term therapy [7]. These observations indicate 
that de-escalation of more potent P2Y12 receptor blocker 
therapy may be considered in patients without HPR as in the 
TROPICAL-ACS study [39]. This strategy may be suitable for 
achieving the balance between ischaemic and bleeding risk, 
and for cost-related reasons. 
Thus, currently we must rely on the guidelines and the 
existing observational data while keeping in mind the role 
that platelet physiology plays in catastrophic event occurrence 
in the stented patient. It is important not to ignore the body 
of evidence demonstrating that: (a) HPR during clopidogrel 
therapy is associated with post-PCI ischaemic event occur-
rences, (b) user-friendly and reliable assays are available to 
assess platelet function, (c) more potent P2Y12 receptor block-
ers are available to overcome HPR, which is present in ~35% 
of patients treated with clopidogrel, (d) nearly two-thirds of 
patients without HPR can be optimally treated with less ex-
pensive generic clopidogrel, and (e) excessive bleeding may 
be reduced and net clinical outcome improved by utilising 
serial PFT in patients selectively treated with the more potent 
P2Y12 receptor blockers as shown in the TROPICAL-ACS study. 
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